

RNPC3 mutations associate prolactin deficiency and ovarian insufficiency: expanding the phenotype beyond isolated growth hormone deficiency type V (MIM#618160)

The authors have nothing to disclose

Martos-Moreno GÁ^{1,2,3}, Travieso-Suárez L¹, Pozo J^{1,2,3}, Chowen J^{1,3,4}, Pérez-Jurado LA⁵, Jesús Argente^{1,2,3,4}

¹Department of Endocrinology, Hospital Infantil Universitario Niño Jesús. IIS La Princesa; ²Department of Pediatrics, Universidad Autónoma de Madrid; ³CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain; ⁴IMDEA Food Institute. Madrid, Spain.; ⁵Genetics Unit, Universitat Pompeu Fabra; IMIM, Barcelona, Spain; CIBERER, Instituto de Salud Carlos III; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia.

Introduction:

- The first three children reported to have biallelic mutations in *RNPC3* presented with growth hormone (GH) deficiency and pituitary hypoplasia (MIM#618160). *RNPC3* encodes a 65-kDa protein that is a structural component of the U11/U12 small nuclear ribonucleoprotein of the minor spliceosome. Mutations in *RNPC3* lead to structural destabilization of the 65-kDa protein, impaired binding of U12 snRNA and global defects in splicing of U12-type introns.
- The underlying mechanism causing GH deficiency (GHD) in these patients is not fully understood. Moreover, whether the association of further hormonal deficiencies occurs throughout lifespan is unknown.

Objective:

We aimed to analyze the evolving hormonal phenotype throughout childhood and adolescence in the first three patients identified with *RNPC3* mutations.

Clinical cases:

We present 3 sisters, compound heterozygous for mutations in *RNPC3* (c.1504C>T / c.1320C>A), born full term with normal length and weight, to non consanguineous parents (target height: 155.6 ± 5 cm) that are heterozygous carriers of the mutations. The patients developed severe postnatal growth failure and typical phenotypic features of GHD. Clinical follow-up and GH replacement of the three sisters started at age 15.5 (**patient 1**), 8.1 (**patient 2**) and 6.0 years (**patient 3**), respectively, resulting in dramatic catch-up growth in all three siblings with their height reaching their target range, as previously reported (*ESPE 2018, P1-P145*).

PUBERTAL DEVELOPMENT

- **Patient-1** was **Tanner stage I** at diagnosis (age **15.5 years**), with baseline **FSH: 30.3 mU/ml** and **LH: 6.7 mU/ml** peaking after **LHRH stimulation at 40.1 and 35.5 mU/ml**, respectively, and concomitant **low serum estradiol levels [7.4 pg/ml]**. Three months after rhGH treatment was started, **Tanner stage II spontaneously developed**, progressing to **Tanner stage IV** after 12 months and presenting a **spontaneous 4-day menarche** after 16 months on therapy.

No further menstrual cycles occurred, with low serum estradiol levels persisting and normal to high FSH and LH levels both at baseline and after LHRH stimulation, thus requiring **hormone replacement**.

- **Patient-2 spontaneously started puberty** (Tanner stage II) at age **11.6 years**, progressing to **Tanner stage IV** at age **13 years**, but remaining **without menarche** up to age **15.7 years**, with baseline **estradiol 9.8 pg/ml**, **FSH 44.2** and **LH 12 mU/ml**, peaking after **LHRH stimulation to 63.1 and 49.5 mU/ml**, respectively; also requiring hormone replacement.

- **Patient-3** started **spontaneous pubertal development** at age **13.0 years**, progressing to **Tanner stage III** in the following 6 months and to **Tanner stage IV** in 12 month time, with **a single spontaneous menstrual cycle** at age **13 years and 10 months**.

- Normal size ovaries but **sparse or absent follicles** were found in the three siblings by ultrasonography.


• **Figure:** Patients' growth charts up to their last visit.

- Pubertal developmental progression is shown (Tanner stages) and spontaneous menarche is represented as a red line (Λ) in patients 1 and 3.

- Yellow triangles represent bone age (G&P) at the time of each height measurement.

Abbreviations:

- **GH:** Start on recombinant human GH treatment.
- **TH:** Target height.



- **Patient 1** showed slightly decreased serum **prolactin** levels at diagnosis [0.78 ng/ml (NV: 1.6-25)], with normal levels in **Patient 2** (2.12 ng/ml) and **Patient 3** (1.83 ng/ml). In contrast, when these patients reached ages of 23, 15.7 and 13.7 years, respectively, in all three serum prolactin was **undetectable** in three separate **baseline** determinations, as well as after **TRH stimulation**.

- The thyrotrophic and corticotrophic axes have shown no impairment during the follow-up to date.

Conclusion:

- Patients with *RNPC3* mutations, initially presenting as isolated **GH deficiency**, can develop **additional pituitary (prolactin) or peripheral (estradiol) hormone deficiencies** during their lifespan and should be closely followed.